Objective: To observe the clinical effects of Dalitong Granule (DG) combined proton pump inhibitors (PPI) on gastroesophageal reflux disease (GERD).
Methods: Totally 186 patients with GERD were randomly assigned to three groups, i.e., the control group A (61 cases, only PPI group, Rabeprazole Capsule 20 mg, once daily), the control group B (61 cases, PPI with domperidone group, Rabeprazole 20 mg, once daily; Domperidone 10 mg each time, thrice daily), and the experimental group (64 cases, PPI + DG group, Rabeprazole 20 mg, once daily; DG, 6 g each time, thrice daily). The treatment lasted for 4 weeks for all. The symptom scoring, the overall efficacy, local efficacy, and adverse drug reactions were compared among the three groups before and after treatment.
Results: Totally 183 patients completed the experiment. After 4 weeks of treatment, the symptom scores in the three groups were significantly lowered. It was the lowest in the experimental group with statistical difference (P < 0.01). The markedly effective rate and the effective rate of the experimental group were significantly higher than those of the control A and B groups. The local markedly effective rate and the effective rate of the reflux esophagitis (RE) in the experimental group were significantly higher than those of the control A and B groups (P<0.05). No serious adverse reactions occurred in the three groups during the treatment period.
Conclusion: DG combined PPI could improve the symptoms of GERD safely and effectively.